Investor Relations | News

Date	Title
08/26/2010	Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism
08/26/2010	Cypress Bioscience Licenses Alexza Pharmaceutical's Staccato(R) Nicotine
08/17/2010	Cypress Bioscience Sends Letter to Ramius
08/10/2010	Cypress Bioscience Receives Consent for BioLineRx In-License Agreement
08/09/2010	Cypress Bioscience Announces Second Quarter 2010 Financial Results
08/06/2010	Cypress Bioscience Responds to Unsolicited, Non-Binding Proposal and Recent Letter From Ramius LLC
08/04/2010	Cypress Bioscience Announces Agreement to Discontinue Co-Promotion of Savella(R) With Forest Laboratories
07/19/2010	Cypress Bioscience Confirms Receipt of Unsolicited Proposal From Ramius LLC
06/20/2010	Cypress Bioscience In-Licenses BioLineRx's Novel Antipsychotic
06/07/2010	Cypress Bioscience, Inc. to Present at Jefferies 2010 Global Life Sciences Conference
06/02/2010	Medicare Administrator Issues Positive Coverage Determination for Cypress Bioscience's Avise PG(SM) Testing Service
05/25/2010	Cypress Bioscience, Inc. to Present at Citi Investment Research's 2010 Global Healthcare Conference
05/10/2010	Cypress Bioscience Announces First Quarter 2010 Financial Results
03/31/2010	Cypress Bioscience Announces 2009 Financial Results
03/15/2010	Cypress Bioscience, Inc. to Present at Roth 22nd Annual OC Growth Stock Conference
03/08/2010	Cypress Bioscience, Inc. to Present at Cowen and Company 30th Annual Health Care Conference
02/26/2010	Cypress Bioscience, Inc. to Participate in RBC Capital Markets Healthcare Conference
02/05/2010	Cypress Bioscience, Inc. to Participate in BIO CEO & Investor Conference
11/30/2009	Cypress Bioscience, Inc. to Present at the Piper Jaffray 21st Annual Health Care Conference
11/09/2009	Cypress Bioscience Announces Third Quarter 2009 Financial Results
10/30/2009	Cypress Bioscience, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference
10/17/2009	Forest Laboratories and Cypress Bioscience Announce Study Shows Patients Treated with Savella Experience Improvements in Pain and Physical Function
09/21/2009	Cypress Bioscience, Inc. to Present at UBS Global Life Sciences Conference
09/08/2009	Cypress Bioscience, Inc. to Present at Baird's 2009 Health Care Conference
08/10/2009	Cypress Bioscience Announces Second Quarter 2009 Financial Results
06/16/2009	Cypress Bioscience, Inc. to Present at Jefferies 3rd Annual Healthcare Conference
05/11/2009	Cypress Bioscience, Inc. Announces First Quarter 2009 Financial Results
05/11/2009	Cypress bioscience, inc. Ceo jay kranzler named Ernst & Young Entrepreneur of the year® finalist in San Diego
04/20/2009	Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
03/06/2009	Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
02/24/2009	Cypress Bioscience, Inc. Acquires Personalized Medicine Technology Platform From Cellatope Corporation
02/13/2009	Cypress Bioscience, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
01/14/2009	Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia
12/08/2008	Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
10/20/2008	FDA Defers Final Action on milnacipran New Drug Application
09/04/2008	CYPRESS BIOSCIENCE TO PARTICIPATE IN CITI'S 3RD ANNUAL BIOTECH DAY
08/08/2008	CYPRESS BIOSCIENCE ANNOUNCES SECOND QUARTER 2008 RESULTS
06/29/2008	CYPRESS BIOSCIENCE TO PRESENT AT OPPENHEIMER SMALL & MID CAP CLINICAL & REGULATORY CONFERENCE
06/23/2008	CYPRESS BIOSCIENCE TO PRESENT AT JEFFERIES 2ND ANNUAL HEALTHCARE CONFERENCE
06/09/2008	CYPRESS BIOSCIENCE TO PRESENT AT NEEDHAM & COMPANY BIOTECHNOLOGY AND MEDICAL TECHNOLOGY CONFERENCE
05/23/2008	CYPRESS BIOSCIENCE TO PRESENT AT FBR CAPITAL MARKETS SPRING INVESTOR CONFERENCE
05/19/2008	CYPRESS BIOSCIENCE TO PRESENT AT CITI'S HEALTH CARE CONFERENCE
05/12/2008	CYPRESS BIOSCIENCE ANNOUNCES FIRST QUARTER 2008 RESULTS
05/06/2008	CYPRESS BIOSCIENCE TO PRESENT AT THE NEUROTECH INDUSTRY INVESTING & PARTNERING CONFERENCE
05/01/2008	CYPRESS BIOSCIENCE TO PRESENT AT DEUTSCHE BANK HEALTH CARE CONFERENCE
03/17/2008	CYPRESS BIOSCIENCE ANNOUNCES FOURTH QUARTER AND FISCAL YEAR END 2007 RESULTS
03/14/2008	CYPRESS BIOSCIENCE TO PRESENT AT COWEN & COMPANY 28TH ANNUAL HEALTH CARE CONFERENCE
03/04/2008	CYPRESS BIOSCIENCE CLOSES ACQUISITION OF PROPRIUS PHARMACEUTICALS
02/21/2008	CYPRESS BIOSCIENCE TO ACQUIRE PROPRIUS PHARMACEUTICALS
02/21/2008	FOREST AND CYPRESS ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR MILNACIPRAN FOR THE TREATMENT OF FIBROMYALGIA
12/31/2007	Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
11/27/2007	Cypress Bioscience, Inc. to Present at CIBC World Marekts 3rd Annual Mid & Small CAP 'Best Ideas' Conference
11/26/2007	Cypress Bioscience, Inc. to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
11/12/2007	Cypress Bioscience, Inc. To Present At CITI'S Biotech Day
11/09/2007	Cypress Bioscience, Inc. Announces Third Quarter 2007 Results
11/08/2007	Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
11/02/2007	Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
05/22/2007	Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
08/09/2006	Cypress Bioscience, Inc. Announces Second Quarter 2006 Results
05/10/2006	Cypress Bioscience, Inc. Announces First Quarter 2006 Results
03/15/2006	Cypress Bioscience, Inc. Announces Fourth Quarter and Fiscal Year End 2005 Results
01/05/2006	Forest Laboratories, Inc. and Cypress Bioscience, Inc. to Commence Third Milnacipran Phase III Trial
11/28/2005	Cypress Bioscience, Inc. to Present at Lazard Capital Markets Life Sciences Conference
11/09/2005	Cypress Bioscience, Inc. Announces Third Quarter 2005 Results
11/07/2005	Cypress Bioscience Inc. to Present at CIBC World Markets Healthcare Conference
10/25/2005	Cypress Bioscience Inc. to Present at C.E. Unterberg, Towbin Life Sciences Conference
10/18/2005	Cypress Bioscience Inc. to Participate in BIO InvestorForum Conference
09/28/2005	Cypress Bioscience Inc. to Hold Conference Call
09/28/2005	Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia
09/27/2005	Cypress Bioscience Inc. to Present at UBS Global Life Sciences Conference
09/19/2005	Cypress Bioscience Inc. to Present at Merriman Curhan Ford & Co. Investor Summit Conference
09/07/2005	Cypress Bioscience Inc. to Present at BioCentury Newsmakers in the Biotech Industry Conference
08/09/2005	Cypress Bioscience, Inc. Announces Second Quarter 2005 Results
07/26/2005	Cypress Bioscience Inc. to Present at Banc of America Specialty Pharmaceuticals Conference
06/29/2005	Organon and Cypress Bioscience Collaborate to Develop Novel Drug Therapy for Treatment of Obstructive Sleep Apnea
06/01/2005	Cypress Bioscience, Inc. to Present at Friedman Billings Ramsey Growth Investor Conference
05/23/2005	Cypress Bioscience, Inc. to Present at UBS Global Pharmaceuticals Conference
05/18/2005	Cypress Bioscience, Inc. to Present at Banc of America Securities Health Care Conference
05/10/2005	Cypress Bioscience, Inc. Announces First Quarter 2005 Results
05/02/2005	Cypress Bioscience Inc. to Present at Deutsche Bank Healthcare Conference
04/04/2005	Cypress Bioscience Inc. to Present at CIBC Biotechnology & Specialty Pharmaceuticals Conference
03/16/2005	Cypress Bioscience, Inc. Announces Fourth Quarter and Fiscal Year End 2004 Results
02/28/2005	Cypress Bioscience Inc. to Present at Wells Fargo Securities HealthCare Conference
02/22/2005	Cypress Bioscience Inc. to Participate in BIO CEO & Investor Conference
02/14/2005	Cypress Bioscience Inc. to Present at Smith Barney Citigroup Small & Mid-Cap Conference
12/15/2004	Cypress Bioscience Inc. to Present at Wachovia Securities 10 for 'O5 Biotech Conference
12/08/2004	Cypress Completes Enrollment of Phase III Milnacipran Clinical Trial Results Expected Fall 2005
12/07/2004	Cypress Bioscience Inc. to Present at First Albany Capital Annual Growth Conference
11/30/2004	Cypress Bioscience Inc. to Present at Lazard Life Sciences Conference
11/18/2004	Cypress Bioscience Inc. to Present at Granite Financial Group Healthcare Investors Conference
11/09/2004	Cypress Bioscience, Inc. Announces Third Quarter 2004 Results
11/08/2004	Cypress Bioscience, Inc. to Present at CIBC World Markets Healthcare Conference
10/26/2004	Cypress Bioscience Inc. to Present at Rodman & Renshaw Techvest Conference
10/11/2004	Cypress' "Pain Assessment in Patients with Fibromyalgia Syndrome: A Consideration of Methods for Clinical Trials'' Published in Clinical Journal of Pain
09/28/2004	Cypress Bioscience Inc. to Present at UBS Global Life Sciences Conference
09/20/2004	Cypress Bioscience Inc. Appoints New Board Members; Building Team to Support Cypress' Development Initiatives
09/09/2004	Cypress Bioscience, Inc. and Forest Laboratories, Inc. to Commence the Second Phase III Clinical Trial for Milnacipran in the Fourth Quarter
09/08/2004	Cypress Bioscience Inc. to Present at BioCentury Newsmakers Conference
08/09/2004	Cypress Bioscience Inc. Announces Second Quarter 2004 Results
08/03/2004	Cypress Bioscience Inc. Drug Milnacipran Highlighted in Today's Wall Street Journal Feature on FMS
07/20/2004	Cypress Bioscience Inc. Announces New Milnacipran Manufacturing Facility in France
06/21/2004	Cypress Bioscience Inc. Phase II Milnacipran Data Presented at CINP Congress in Paris
05/18/2004	Cypress Bioscience Inc. Added to Nasdaq Biotechnology Index
05/17/2004	Cypress Bioscience, Inc. Announces First Quarter 2004 Results